Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee

 

Food and Drug Administration

Center for Drug Evaluation and Research

Hilton, The Ballrooms, 620 Perry Parkway, Gaithersburg, MD.

 

Clinical Risk Management of HPA Axis Suppression in Children

with Atopic Dermatitis being treated with Topical Corticosteroids

 

 

Bibliography

 

 

 

 

The Harriet Lane Handbook, 15th Edition, Topical Steroid Potency Ranking, page 908-909.

 

Memorandum: ODS Postmarketing Safety Review (PID0303434), Marilyn R. Pitts, September 24, 2003

 

Memorandum: ODS Postmarketing Safety Review (PID# D030433), Renan A. Bonnel, September 24, 2003

 

Leung, D., and Bieber, T.,  Seminar: Atopic Dermatitis, The Lancet, 2003,  361, 151-160.

 

Drake LA., et al, Guidelines of care for the use of topical glucocorticosteroids, American Academy of Dermatology, Inc., 1996, 35, 615-619.

 

Helfer, EL., and Rose, LI., Corticosteroids and Adrenal Suppression, Characterizing and Avoiding the Problem, Drugs, 1989, 38 (5): 838-845.

 

Grinspoon, SD., and Biller, BM., Clinical Review 62, Laboratory Assessment of Adrenal Insufficiency, Journal of Clinical Endocrinology and Metabolism, 1994, 79 (4) 923- 931.